Clinical Trials · NCT01511185
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 20
- Start date
- Feb 2001
- Locations
- 1 site, United States
- Primary endpoint
- AUC (area under the curve) of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval